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Abstract: Dexmedetomidine undoubtedly is a useful sedative in the intensive care setting 
because it has a minimal effect on the respiratory system. Dexmedetomidine infusions lasting 
more than 24 hours have not been approved since the first approval was acquired in the US 
in 1999. However, in 2008, dexmedetomidine infusions for prolonged use were approved in 
  Colombia and in the Dominican Republic, and the number of countries that have granted approval 
for prolonged use has been increasing every year. This review discusses the literature examining 
prolonged use of dexmedetomidine and confirms the efficacy and safety of dexmedetomidine 
when it is used for more than 24 hours. Dexmedetomidine was administered at varying doses 
(0.1–2.5 µg/kg/hour) and durations up to 30 days. Dexmedetomidine seems to be an alterna-
tive to benzodiazepines or propofol for achieving sedation in adults because the incidences of 
delirium and coma associated with dexmedetomidine are lower than the corresponding incidences 
associated with benzodiazepines and propofol, although dexmedetomidine administration can 
cause mild adverse effects such as bradycardia. Controlled comparative studies on the efficacy 
and safety of dexmedetomidine and other sedatives in pediatric patients have not been reported. 
However, dexmedetomidine seems to be effective in managing extubation, reducing the use 
of conventional sedatives, and as an alternative for inducing sedation in patients for whom 
traditional sedatives induce inadequate sedation. Prolonged dexmedetomidine infusion has not 
been reported to have any serious adverse effects. Dexmedetomidine appears to be an alternative 
long-term sedative, but further studies are needed to establish its efficacy and safety.
Keywords: dexmedetomidine, prolonged sedation, long-term
Introduction
Dexmedetomidine is a highly selective α2-agonist with sedative, analgesic, and sympatho-
lytic properties.1,2 Because of its minimal effects on the respiratory system, dexmedetomi-
dine seems to be an ideal sedative. However, dexmedetomidine has not been widely used 
because its indications are limited to treatment of patients who are intubated, mechanically 
ventilated, and admitted to an intensive care unit. In addition, infusion cannot be continued 
beyond 24 hours, and the maximum recommended dose is only 0.7 µg/kg/hour.
Fortunately, the indications for the use of dexmedetomidine have been expanding, 
and the impetus for this change may have come from clinicians. Tables 1 and 2 show 
the approval status for dexmedetomidine in various settings in some countries. In 
October 2008, the US Food and Drug Administration (FDA) approved the use of 
dexmedetomidine in nonintubated patients prior to and during surgical and other 
  procedures. Furthermore, the approved range of dexmedetomidine titration in moni-
tored care anesthesia, which is included in the above indication, has been increased 
to 1.0 µg/kg/hour.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Dexmedetomidine as a long-term sedative
Long-term administration has been approved in five 
countries since the first approval was acquired in Colombia 
in 2008. In 2010, Japan became the sixth country to grant 
approval for long-term administration of dexmedetomidine. 
This review focuses on the prolonged use of dexmedetomi-
dine, which is one of the two expanding indications for this 
sedative, and discusses the effectiveness and safety of its 
prolonged use.
Treatment duration
In the Japanese package insert,3 the following instructions 
are provided with regard to prolonged dexmedetomidine 
administration: “Dexmedetomidine can be administered 
during intubation or during and after intubation, however 
strict monitoring for systemic condition of patients should 
be continued if duration exceeds 5 days because of lack 
of experience of administration over 5 days”. A Phase III 
clinical trial was performed in Japan in 2007–2008 to evalu-
ate the safety and efficacy of long-term dexmedetomidine 
in patients requiring 24 hours or more of sedation in the 
intensive care unit. This study examined a protocol in which 
dexmedetomidine was used for up to 28 days. In this trial, 
dexmedetomidine was administered for a mean duration of 
88 ± 98 hours,4 and the maximum duration of dexmedeto-
midine administration was 478 hours.
Riker et al5 reported a multicenter trial in which the 
safety and efficacy of dexmedetomidine was compared with 
that of midazolam in critically ill, mechanically ventilated 
patients in five countries (US, Australia, Brazil, Argentina, 
and New Zealand). The protocol involved dexmedetomidine 
administration for up to 30 days. In that study, 244 patients 
were treated with dexmedetomidine for a median duration 
of 3.5 days (interquartile range [IQR]: 2.0–5.2 days). A ret-
rospective cohort study by Wunsch et al6 examined 58,391 
patients who received intravenous infusion sedation; 2535 
of them received dexmedetomidine. The mean duration of 
dexmedetomidine infusion (±standard deviation [SD]) was 
1.5 ± 2.0 days, and 31.5% of the patients received dexme-
detomidine infusion for more than 1 day.
Venn et al7 performed a pilot study in 12 patients in a 
medical intensive care unit in the UK, and Shehabi et al8 
performed a pilot study in 20 patients in both medical and 
surgical intensive care units in Australia. In both studies, 
dexmedetomidine was used if required for up to 7 days. In a 
study by Wunsch et al, five of 12 patients received dexme-
detomidine infusion for more than 24 hours, and one patient 
received dexmedetomidine for a maximum duration of 
72 hours. In the studies by Venn et al and Shehabi et al, all 20 
patients received dexmedetomidine for more than 24 hours, 
and one patient received dexmedetomidine for 7 days.
The protocol in a multicenter, prospective, randomized, 
double-blind, double-dummy, active comparator study 
performed by Ruokonen et al9 in Finland and Switzerland 
allowed dexmedetomidine to be administered for up to 
14 days, and 41 patients received dexmedetomidine for a 
median duration of 40 (range 3–198) hours.
Pandharipande et al10,11 conducted two controlled studies 
to compare the effects of dexmedetomidine with those of 
lorazepam on acute brain dysfunction in mechanically venti-
lated patients and to compare the effects of dexmedetomidine 
with those of lorazepam on clinical outcome in patients with 
or without sepsis. In these studies, dexmedetomidine was 
administered, if required, for up to 5 days.
Dosing
The doses used in the aforementioned studies were used 
to evaluate the efficacy of long-term administration of 
  dexmedetomidine. The study conducted by Venn et al7 was 
a small, uncontrolled study involving 12 patients and showed 
an interesting change in protocol and results. Their dosing 
protocol for long-term administration had been a maintenance 
dose of 0.2–0.7 µg/kg/hour with a loading dose of 1.0 µg/kg 
over 10 minutes. However, the protocol was revised, and the 
maximum maintenance dose was increased to 2.5 µg/kg/hour 
from the fifth patient onwards because sedation goals were 
not achieved with the earlier dose in the first four patients. 
The mean dexmedetomidine infusion rate in the last eight 
patients was 1.0 ± 0.7 µg/kg/hour, and the median value of 
the maximum dose in the last eight patients was 1.35 (range 
0.4–2.5) µg/kg/hour. The authors stated that medical patients 
might need higher infusion rates of dexmedetomidine.
In the study by Shehabi et al,8 20 critically ill patients 
received dexmedetomidine at a dose of 0.2–0.7 µg/kg/hour, 
but a loading dose of dexmedetomidine was omitted because 
the patients had already received other sedative drugs, 
which were administered until 1 hour after administration 
of dexmedetomidine was started. Most patients had an 
acceptable quality of sedation, ie, 83% of the patients had 
sedation levels between 2 and 5 on the Ramsay Sedation 
Scale during the study period, with minimal or no additional 
midazolam administration (median 4, range 0.5–10 mg/day) 
in 16 patients and minimal or no additional analgesia 
(median 2, range 0.5–4.5 mg/day for morphine; median 55, 
range 14–63 µg/day for fentanyl) in ten patients. However, 
the authors suggested that some patients could have benefited 
from a higher dose, because high doses of midazolam were Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
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required to facilitate the management of a deteriorating 
clinical state in four patients.
Two randomized controlled trials performed by 
  Pandharipande et al10,11 comparing the efficacy of dexme-
detomidine with that of lorazepam used a protocol that 
permitted dexmedetomidine administration at doses up to 
1.5 µg/kg/hour. In the latter study, the median infusion rate 
for dexmedetomidine was 0.74 (IQR: 0.39–1.04) µg/kg/hour; 
the median dexmedetomidine dose given to patients who had 
sepsis was 0.8 (IQR: 0.3–1.1) µg/kg/hour, and the median 
dose administered to patients who did not have sepsis was 
0.6 µg/kg/hour. Ruokonen et al9 adjusted dexmedetomidine 
stepwise at five doses (0.25, 0.5, 0.8, 1.1, and 1.4 µg/kg/hour) 
after infusion of a dose of 0.8 µg/kg/hour for 1 hour without an 
initial dose, and the patients in their study received a median 
dexmedetomidine dose of 0.8 (range 0.3–1.4) µg/kg/hour.
Ricker et al5 adopted a strategy using doses up to 
1.4 µg/kg/hour, which was twice the limit approved at that 
time by the FDA. The mean ± SD maintenance infusion 
dose of dexmedetomidine was 0.83 ± 0.37 µg/kg/hour. The 
dexmedetomidine dose was 0.2–0.7 µg/kg/hour in 95 of 244 
patients (39%), 0.71–1.1 µg/kg/hour in 78 of 244 patients 
(32%), and more than 1.1 µg/kg/hour in 71 of 244 patients 
(29%). A Phase III clinical trial performed in Japan used 
the maximum dose of 0.7 µg/kg/hour. However, the actual 
administered infusion rate has not been reported.4
Efficacy
Sedation
Riker et al5 confirmed that there was no difference in the 
primary sedation efficacy achieved by dexmedetomidine 
or midazolam. The percentage of the duration for which 
patients were noted to be within the target Richmond 
  Agitation-Sedation Score (RASS) range was 77.3% for those 
treated with dexmedetomidine and 75.1% for those treated 
with midazolam (difference 2.2%, 95% confidence interval 
[CI]: -3.2%–7.5%; P = 0.18).
Pandharipande et al10 revealed that, in comparison with 
patients sedated with lorazepam, those sedated with dexme-
detomidine spent more time at the level of sedation targeted 
by both nurses and physicians. The median percentages of 
RASS scores in the patients treated with dexmedetomidine 
that were within one point of the nurse and physician goal 
were 80 (IQR: 58–100) and 67 (IQR: 50–85), respectively, 
and these scores were higher than the corresponding values in 
the lorazepam group (67% [48%–83%] and 55% [8%–67%], 
respectively). The percentage of days on which the RASS 
scores deviated by $2 points from the nurse goal in the case 
of patients treated with dexmedetomidine was lower than that 
in the lorazepam group (median 15% [IQR: 0%–33%] vs 
33% [IQR: 11%–48%]). The number of days patients were 
noted to be oversedated was lower in the dexmedetomidine 
group than in the lorazepam group (median 1 [IQR: 0–2.2] 
vs 2 [IQR: 1–3.5]).
In the study reported by Pandharipande et al,11 the 
efficiency of sedation in the patients who did not have sepsis 
was similar for both treatment groups (67% of days [IQR: 
50%–86%] vs 60% of days [IQR: 27%–75%]; P = 0.27). 
However, among the patients with sepsis, those sedated with 
dexmedetomidine achieved sedation within one point of the 
RASS target more often than those sedated with lorazepam 
(accurate sedation on 67% of days [IQR: 50%–83%] vs 52% 
of days [IQR: 0%–67%]; P = 0.01).
The study conducted by Ruokonen et al,9 in which the 
efficacy of dexmedetomidine was compared with that of 
standard care using either propofol or midazolam for seda-
tion, did not confirm the noninferiority of dexmedetomidine 
in comparison with standard care. The target RASS level was 
reached in a median of 64% (dexmedetomidine) and 63% 
(standard care) for sedation time (not statistically significant). 
For patients with an RASS target level of -3 to 0 (dexme-
detomidine 78%; standard care 80%), the target sedation 
level was achieved in 74% of cases when dexmedetomidine 
was administered and in 64% of cases when standard care 
was administered (not statistically significant), whereas for 
patients with an RASS target level #4, the target sedation 
level was achieved in 42% of cases when dexmedetomi-
dine was administered and in 62% of cases when standard 
care was administered (P = 0.006); these results suggested 
the unsuitability of dexmedetomidine for deep sedation.
Delirium and coma
Riker et al5 demonstrated the superiority of dexmedetomi-
dine with regard to the treatment or prevalence of delirium. 
  During this study, the effect of dexmedetomidine treatment 
on delirium, as measured by a generalized estimating equa-
tion, was a 24.9% reduction (95% CI: 16%–34%; P , 0.001). 
The prevalence of delirium was 54% (132/244) in patients 
treated with dexmedetomidine, in contrast with a prevalence 
of 76.6% (93/122) in patients treated with midazolam (dif-
ference 22.6%, 95% CI: 14%–33%; P , 0.001). Moreover, 
despite the shorter duration of study drug treatment (dexme-
detomidine vs midazolam, median [IQR] 3.5 [2.0–5.2] vs 4.1 
[2.8–6.1]; P = 0.01), the number of delirium-free days was 
greater for patients treated with dexmedetomidine (2.5 days 
vs 1.7 days; P = 0.002). In the study by Pandharipande et al,10 Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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there were no intergroup differences in the duration of 
delirium-free days (median [IQR] 9 [5–11] vs 7 [5–10]; 
P = 0.09) or the prevalence of delirium (number [%], 41 
[79%] vs 42 [82%]; P = 0.65). However, because there were 
significant intergroup differences in the duration of coma-free 
days (median [IQR] 10 [9–12] vs 8 [5–10]; P , 0.001) and 
prevalence of coma (number [%], 33 [63%] vs 47 [92%]; 
P , 0.001), sedation with dexmedetomidine resulted in a 
higher duration of survival without delirium or coma (median 
days [IQR], 3.0 [1–6] vs 7.0 [1–10]; P = 0.01) and a lower 
prevalence of coma (n = 45 [63%]) than with sedation using 
lorazepam (n = 47 [92%]; P , 0.001).
Another study conducted by Pandharipande et al11 showed 
that patients with sepsis who were treated with dexmedetomi-
dine had 3.2 more delirium-free/coma-free days on average 
(95% CI for difference: 1.1–4.9 days). Moreover, among all 
patients (including patients who did not have sepsis), those 
sedated with dexmedetomidine had a 70% lower likelihood of 
having delirium on any given day in comparison with patients 
sedated with lorazepam (P for treatment = 0.004).
A pilot study by Ruokonen et al9 showed that delirium 
was more common in patients treated with dexmedetomidine 
(43.9% vs 25.0% for standard care; P = 0.035) when ana-
lyzed as the combined endpoint of the confusion assessment 
method for the intensive care unit (CAM-ICU) and adverse 
events of delirium and confusion. However, more CAM-ICU 
assessments were performed in the dexmedetomidine-treated 
group (106 for dexmedetomidine vs 84 for standard care), and 
the proportion of positive CAM-ICU results was comparable 
(17.0% for dexmedetomidine vs 17.9% for standard care, not 
statistically significant).
Clinical outcome
Riker et al5 showed that the time to extubation in patients 
treated with dexmedetomidine was 1.9 days shorter than 
that in patients treated with midazolam (3.7 days [95% CI: 
3.1–4.0 days] vs 5.6 days [95% CI: 4.6–5.9 days], respec-
tively; P = 0.01). However, the median length of intensive 
care stay was similar (5.9 days [95% CI: 5.7–7.0 days] vs 
7.6 days [95% CI: 6.7–8.6 days]; P = 0.24), although the 
length of stay for the dexmedetomidine-treated group tended 
to be shorter than that for the midazolam-treated group. There 
was no intergroup difference in 30-day mortality   following 
intensive care admission between patients treated with 
dexmedetomidine (22.5% [55/244]) and those treated with 
midazolam (25.4% [31/122]; P = 0.60), and no death was 
considered to be related to dexmedetomidine. The percent-
age of patients transferred alive from the intensive care 
unit was also similar in both groups, (81.5% [199/244] for 
patients treated with dexmedetomidine vs 81.9% [100/122] 
for patients treated with midazolam; P . 0.99).
In one of the studies conducted by Pandharipande 
et al,10 no significant differences were noted between the 
dexmedetomidine-treated and lorazepam-treated groups for 
ventilator-free days (22 vs 18 days; P = 0.22), length of stay 
in the intensive care unit (7.5 vs 9 days; P = 0.92), and rate of 
mortality after 28 days (17% vs 27%; P = 0.18). Moreover, 
the 12-month time to death in the dexmedetomidine-treated 
group and the lorazepam-treated group was 363 and 188 days, 
respectively. The likelihood of dying at 12 months was 
similar between the groups (hazards ratio [HR]: 0.8; 95% 
CI: 0.5–1.4; P = 0.48).
The other study conducted by Pandharipande et al11 showed 
that patients with sepsis who were sedated with dexmedeto-
midine had a mean of 6.0 (95% CI: 0.3–11.0 days) more 
ventilator-free days than did patients receiving lorazepam. 
Interestingly, patients with sepsis who were sedated with 
dexmedetomidine also had a lower risk of death at 28 days 
than those sedated with lorazepam (HR: 0.3, 95% CI: 0.1–0.9); 
this beneficial effect was not seen in patients who did not have 
sepsis (HR: 4.0, 95% CI: 0.4–35.5; P for interaction = 0.11).
In the study by Ruokonen et al,9 there were no significant 
differences between the dexmedetomidine and standard care 
groups in terms of duration for which mechanical ventilation 
was needed, time required for weaning, number of ventilator-
free days, or time to discharge from the hospital. After post 
hoc adjustment, the duration of mechanical ventilation was 
shorter in patients treated with dexmedetomidine (77.2 
[range: 17.5–338.8] hours vs 110.6 [range: 20.1–675.0] 
hours; P = 0.025), and median duration of mechanical ven-
tilation in patients with light-to-moderate sedation in the 
dexmedetomidine-treated group was shorter than that in the 
standard care group (70.2 [range: 17.5–225.4] hours vs 93.7 
[range: 20.1–675.0] hours; P = 0.027).
Adverse events
The study conducted by Riker et al5 showed that the num-
ber of dexmedetomidine-treated patients who developed 
treatment-related adverse events was greater than the number 
of   midazolam-treated patients who developed these events 
(40.6% [99/244] vs 28.7% [35/122]; P = 0.03), primar-
ily because of a greater incidence of bradycardia (42.2% 
[103/244] vs 18.9% [23/122]; P , 0.001). In contrast, the 
incidence of tachycardia in patients treated with midazolam 
was higher than that seen in patients treated with dexmedeto-
midine (44.3% [54/122] vs 25.4% [62/244]; P , 0.001). There Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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were no significant intergroup differences in the   incidences 
of hypotension or hypertension. Regarding adverse events 
that required intervention, only the incidence of hypertension 
had a significant intergroup difference (midazolam 29.5% 
[36/122] vs dexmedetomidine 18.9% [46/244]), although 
the incidence of bradycardia that required intervention was 
higher in patients treated with dexmedetomidine than in 
patients treated with midazolam.
Ruokonen et al9 showed that serious adverse events were 
equally common. Seventeen patients (42%) treated with dex-
medetomidine had serious adverse events (including three 
patients with bradycardia and two patients with hypotension), 
and 18 patients (41%) treated with midazolam or propofol had 
serious adverse events (including two patients with cardiac 
failure and one patient with hypotension). There were no inter-
group differences in the incidence of serious adverse events.
Pandharipande et al11 showed that there were no significant 
intergroup differences in hemodynamic variables for patients 
with sepsis. In patients who did not have sepsis, the only sig-
nificant intergroup difference was for the incidence of sinus 
bradycardia (24% for dexmedetomidine vs 0% for   lorazepam; 
P = 0.02). Another study conducted by   Pandharipande et al10 
showed that patients in the   dexmedetomidine-treated and 
lorazepam-treated groups had comparable blood pressure, 
vasoactive drug usage, and incidence of tachycardia. Patients 
in the dexmedetomidine-treated group had a higher incidence 
of sinus bradycardia (heart rate ,60 beats per minute) than 
those in the lorazepam-treated group, although one patient 
from each group had an episode of heart rate lower than 40 
beats per minute.
Rebound complications and/or 
withdrawal events
Riker et al5 reported that rebound hypertension and tachycar-
dia did not occur following abrupt discontinuation of dex-
medetomidine infusion. Ruokonen et al9 observed no signs 
of cardiovascular instability and/or rebound after cessation 
of sedation with dexmedetomidine. Venn et al7 observed 
that following discontinuation of dexmedetomidine, there 
were small, but sustained increases in systolic and diastolic 
arterial pressure and heart rate, but there were no clinically 
important rebound phenomena.
In the study by Shehabi et al,8 the incidences of these phe-
nomena were recorded for 24 hours after abrupt cessation of 
the study drug, and minimal changes were observed. A maxi-
mum mean systolic blood pressure value of 154 ± 24.7 mmHg 
(7% increase) from a baseline mean of 143 ± 24 mmHg was 
recorded 5 hours after cessation. The mean baseline heart 
rate at cessation of dexmedetomidine administration was 
86 ± 27 beats per minute, and a maximum mean heart rate of 
97 ± 27 beats per minute (11% increase) was observed after 
14 hours. These findings indicated no evidence of cardiovas-
cular rebound 24 hours after abrupt cessation of infusion.
Riker et al5 reported rare drug-related withdrawal events, 
such as agitation, headache, hyperhidrosis, nausea, nervous-
ness, tremor, or vomiting after stopping the study drug. 
Overall, 4.9% (12/244) of dexmedetomidine-treated patients 
and 8.2% (10/122) of midazolam-treated patients experienced 
at least one event related to withdrawal within 24 hours of 
discontinuing the study drug (P = 0.25).
Other outcomes
There were two interesting outcomes in the study by Riker 
et al.5 Hyperglycemia occurred more frequently among 
dexmedetomidine-treated patients. The rates of treatment 
with corticosteroids were similar (65.5% [160/244] in 
dexmedetomidine-treated patients vs 68.9% [84/122] in mida-
zolam-treated patients), as was the use of insulin therapy 
(77.8% [190/244] of dexmedetomidine-treated patients vs 
74.8% [91/122] in midazolam-treated patients); however, 
the reasons for these results are not known. The incidence 
of infection occurring during the double-blind period was 
lower in dexmedetomidine-treated patients (10.2% [25/244] 
vs 19.7% [24/122] in midazolam-treated patients; P = 0.02). 
This included lower rates of urinary tract infections (0% 
in dexmedetomidine-treated patients vs 3.3% [4/122] in 
  midazolam-treated patients; P = 0.02) and hospital-acquired 
pneumonia (1.2% [3/244] in dexmedetomidine-treated 
patients vs 4.9% [6/122] in midazolam-treated patients; 
P = 0.07). The results may be because use of dexmedetomi-
dine reduced the time needed for mechanical ventilation and 
reduced the length of intensive case stay. However, in the study 
conducted by Pandharipande et al, the development of new 
secondary infections beyond the first 48 hours after enrollment 
was similar in the patients without sepsis in the dexmedeto-
midine and lorazepam study arms (17% vs 15%).11
Cost
Dasta et al12 performed a secondary analysis of a previously 
published study conducted by Riker et al5 to analyze intensive 
care unit cost differences in patients after randomization to 
dexmedetomidine or midazolam for sedation. The   unadjusted 
median total intensive care unit cost was significantly lower for 
patients in the dexmedetomidine-treated group (US$27,694; 
P , 0.025) in comparison with US$34,122 in the midazolam-
treated group. The median costs calculated after adjusting Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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for censored intensive care unit and   ventilation times were 
about 50% higher in each group and remained   significantly 
lower in the dexmedetomidine-treated group. In the primary 
analysis, after adjustment for covariates and censoring 
patients, the dexmedetomidine-treated group achieved a 
median cost saving of US$9679 (95% CI: US$2314–
US$17,045; P , 0.01 for intensive care unit). After adjusting 
for covariates and censoring patients, dexmedetomidine use 
resulted in significant median savings in both intensive care 
unit costs (US$6584, 95% CI: US$727–US$12,440) and 
the component cost of mechanical ventilation (US$2958, 
95% CI: US$698–US$5219). The median component costs 
associated with treating adverse drug reactions were also 
significantly lower in the dexmedetomidine-treated group 
(US$229, 95% CI, US$49–US$409; P , 0.013). These 
cost savings were observed despite the higher study drug 
acquisition cost for dexmedetomidine (mean cost US$1826 
vs US$80 for midazolam; median cost US$1166 vs US$60 
for midazolam).
Pandharipande et al10 demonstrated that the median 
total hospital cost in their dexmedetomidine-treated group 
was approximately US$22,500 higher than that in their 
  lorazepam-treated group; however, the difference was not 
statistically significant. They concluded that despite the higher 
cost of dexmedetomidine, the benefits of sustained sedation 
with this agent were realized, with comparable overall phar-
macy, respiratory, intensive care unit, and hospital costs.
Pediatric patients
There are no large, controlled, prospective or randomized 
studies of dexmedetomidine in pediatric patients, and there 
are no studies comparing dexmedetomidine with placebo 
or other sedative drugs, such as midazolam or propofol, in 
this age group.
One prospective observational study was reported by 
Buck and Wilson,13 in which 17 patients received dexme-
detomidine for dose reduction of other sedatives that could 
cause respiratory depression, for use as an alternative during 
prolonged intubation after other sedatives failed to achieve 
adequate sedation, or for treating patients who developed 
tolerance to other sedatives although they received mida-
zolam or an opioid before or during administration of 
dexmedetomidine.
Four retrospective medical chart reviews14–17 have been 
published presenting experiences with prolonged dexme-
detomidine infusion in infants and children. All of them 
indicated the efficacy of prolonged dexmedetomidine use. 
However, in these studies, dexmedetomidine was not used 
as a first-choice sedative; rather, it was added to an existing 
sedative regimen to facilitate dose reduction of the standard 
sedation agents and extubation. Some indications and dose 
recommendations were introduced, and their efficacy and 
safety were investigated.
Dosing and duration
In the study by Buck and Wilson,13 dexmedetomidine 
was administered without a loading dose to all patients 
(mean age, 31.4 ± 60.9 months; median age, 5 months 
[range 1 month to 17 years]) at a starting dose of 0.2 ± 0.2 
(range, 0.1–0.5) µg/kg/hour. The mean ± SD duration of 
therapy was 32 ± 21 (range 3–75) hours. The duration of 
therapy exceeded the 24-hour limit in 50% of cases. Bejian 
et al15 identified 54 patients who received dexmedetomidine; 
the median age was 6 months (range 1 day to 16 years). 
The initial and maximum doses of dexmedetomidine were 
0.38 ± 0.13 (range 0.2–0.7) µg/kg/hour and 0.8 ± 0.48 (range 
0.3–2.0) µg/kg/hour, respectively, and the infusion duration 
was 37.3 ± 37.4 (range 2–177) hours.
The chart reviews of 65 burns patients with a mean age of 
5 (range 0.6–17) years performed by Walker et al16 revealed 
that for patients receiving dexmedetomidine at the initial dose 
of 0.2 µg/kg/hour with a loading dose of 1 µg/kg (in 40% of 
patients) or no loading dose (in 60% of the patients), the aver-
age duration of dexmedetomidine infusion was 11 (range 2–50) 
days, with a mean dose of 0.5 (range 0.1–2.0) µg/kg/hour.
In the study performed by Carroll et al,16 dexmedetomi-
dine was administered 74 times to 60 children. The median 
age of the children was 1.5 (range 0.1–17.2) years. The 
median dose required to maintain adequate sedation was 
0.7 (range 0.2–2.5) µg/kg/hour after no loading dose, with a 
median duration of therapy of 23 (range 3–451) hours. Reiter 
et al14 reported that eight of 29 patients (aged 5.3 ± 6.1 years) 
received a loading dose of dexmedetomidine 0.5–1.0 µg/kg 
prior to the start of the infusion. Dexmedetomidine was ini-
tiated at 0.36 ± 0.16 (range 0.1–0.75 µg/kg/hour), and the 
maximum dose was 0.65 ± 0.34 (range 0.2–1.5) µg/kg/hour. 
The mean duration of dexmedetomidine therapy was 
110 ± 83 (range 32–378, median 76) hours.
Efficacy
There are no studies in which the efficacy of dexmedeto-
midine has been compared with that of other agents in 
pediatric patients, because dexmedetomidine was initiated 
as an adjunctive and/or alternative to conventional   sedation. 
Moreover, because validated sedation scales were not 
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the   ability to achieve sedation goals, conclusions cannot 
be drawn regarding the efficacy of dexmedetomidine in 
achieving sedation goals in pediatric patients. The objectives 
of dexmedetomidine administration were: reduction in the 
doses of benzodiazepines and/or opioids to reduce the risk of 
respiratory depression during extubation: use as an alterna-
tive sedative agent in patients who did not achieve adequate 
sedation or those who become paradoxically agitated with 
traditional sedatives; and sedation in nonintubated children 
to provide a titratable level of sedation without respiratory 
depression. Therefore, the efficacy of dexmedetomidine has 
mainly been investigated for its effectiveness in reducing the 
use of conventional sedation agents.
Buck and Wilson13 reported that use of dexmedetomidine 
allowed discontinuation of midazolam or reduction in dose 
of midazolam prior to extubation in 13 of 14 cases, although 
discontinuation of opioid analgesics was not attempted. The 
investigation by Bejian et al15 revealed that patients given 
dexmedetomidine received significantly less fentanyl and 
midazolam than controls. The mean total doses of fentanyl 
(16.6 ± 4.2 µg/kg/day) and midazolam (0.26 ± 0.1 µg/kg/day) 
were lower than the corresponding values in the control group 
(fentanyl, 47.5 ± 15.1 µg/kg/day, P = 0.014; midazolam, 
1.08 ± 0.47 µg/kg/day, P = 0.006), although the durations 
of fentanyl and midazolam infusions were not significantly 
different between the groups.
Walker et al15 noted that initiation of dexmedetomidine 
could change the sedation rating from inadequate sedation 
to adequate sedation in all their 65 pediatric burns patients. 
Carroll et al17 found that use of dexmedetomidine to facilitate 
weaning from other sedative agents could reduce the use of 
fentanyl infusion (43% vs 17%; P = 0.009) and scheduled 
lorazepam infusion (30% vs 10%; P = 0.02). Reiter et al14 
showed that the overall degree of sedation (continuous 
sedation, pulse as-needed sedation) was generally reduced 
during dexmedetomidine therapy, although the number of as-
needed doses was higher during dexmedetomidine therapy, 
compared with the number of as-needed doses before and 
after therapy.
Safety
Buck and Wilson13 revealed that mean arterial pressures before 
and after starting dexmedetomidine were not significantly dif-
ferent (P = 0.76), nor were the mean arterial pressure values 
at 1 (P = 0.31) or 12 hours after discontinuation (P = 0.29) 
significantly different from those before discontinuation. 
No significant differences were noted in heart rate at the 
start of therapy (P = 0.09), at the discontinuation of therapy 
(P = 0.06), or 12 hours later (P = 0.17). Hypotension occurred 
during treatment in one patient who had sepsis. However, this 
effect was considered to be caused by sepsis itself because 
the hypotension continued after dexmedetomidine was dis-
continued, and blood pressure improved with administration 
of antibiotics and supportive therapy.
Bejian et al15 found that mean heart rates after discon-
tinuation of infusion were statistically lower than those prior 
to or during the infusion, ie, 120 and 124 beats per minute 
(15 minutes before and 2 hours after discontinuation, respec-
tively) vs 138 and 133 beats per minute (2 hours before and 
2 hours after initiation), respectively (P , 0.05).   Respiratory 
rates 15 minutes and 2 hours after discontinuation were 
statistically higher than those before infusion and during 
infusion, ie, 29 breaths per minute vs 24 breaths per minute 
(P , 0.05). However, they concluded that there were no 
clinically significant changes in the physiological parameters 
associated with initiation, maintenance, or discontinuation 
of dexmedetomidine infusion, because no intervention was 
required for the abovementioned change in parameters and 
because initiation, maintenance, or discontinuation of dex-
medetomidine did not cause any significant changes in other 
physiological parameters.
Walker et al16 reported two deaths and one episode of 
hypotension requiring epinephrine infusion. However, 
they felt that these episodes were related to the sever-
ity of the patients’ illnesses and not to administration of 
  dexmedetomidine. They did not find clinically significant 
episodes of bradycardia or hypertension. Rebound hyper-
tension or withdrawal was not observed and tachyphylaxis 
was not noted. The patients’ blood glucose levels averaged 
121.2 ± 8.9 mg/dL while on dexmedetomidine infusion and 
117.1 ± 12.1 mg/dL while off it, and the difference was not 
significant. Carroll et al17 reported that 20% of their pediatric 
patients receiving dexmedetomidine experienced adverse 
effects, ie, hypotension (9%), hypertension (8%), and bra-
dycardia (3%). Almost all of these events resolved without 
treatment or withholding dexmedetomidine infusion; one 
patient required fluid therapy for treatment of hypotension. 
Reiter et al14 found that initiation of therapy with dexme-
detomidine was associated with a transient yet statistically 
significant reduction in heart rate (from 120 ± 28 beats per 
minute to 107 ± 27 beats per minute; P = 0.002), but without 
a change in blood pressure.
Conclusion
Dexmedetomidine can be an alternative long-term sedative 
for achieving sedation goals. Dexmedetomidine offers the Therapeutics and Clinical Risk Management
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major advantage of a reduction in the incidence of delirium 
and coma during long-term sedation in the intensive care unit 
setting. Adverse effects such as bradycardia that occur during 
short-term sedation with dexmedetomidine are unavoidable. 
Interestingly, a secondary beneficial effect associated with 
the use of dexmedetomidine is a reduction in the incidence 
of infection; this appears to be because the use of dexmedeto-
midine reduces intensive care unit stay and/or duration of 
mechanical ventilation. Rebound and/or withdrawal effects 
after discontinuation at the end of prolonged sedation do not 
seem to be a concern.
In pediatric patients, a prospective study is awaited for 
confirmation of the efficacy and safety of dexmedetomidine. 
However, dexmedetomidine can be expected to serve as an 
adding agent and/or alternative for dose reduction of tradi-
tional agents to minimize the respiratory effects of extubation 
and as an alternative in patients who are not comfortable with 
receiving conventional agents. Dexmedetomidine has poten-
tial as a main drug for both long- and short-term sedation, and 
the findings of further studies are awaited with interest.
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